BIO-Europe 2007 takes place November 12-14, 2007 at the Congress Center Hamburg. Listed below are BIO-Europe exhibitor profiles. For in-depth information about the event, visit http://www.ebdgroup.com/bioeurope/.
Business Wire is the official news wire for BIO-Europe 2007. Breaking news releases and photos are available at http://www.tradeshownews.com, Business Wire's trade show, conference, and event news resource.
Company: | AAIPharma |
Stand: | 53 |
Media Contact: | Dr. John M. Hall |
Phone: | 44 7802 207 307 |
E-mail: | john.hall@aaipharma.com |
Web: | www.aaipharma.com |
AAIPharma's scientific and professional teams have provided best-in-class product development expertise since 1979. Our business is founded on partnership and delivery of value. We deliver services ranging from a single test to integrated drug development: consulting, preclinical (oncology), pharmaceutical sciences (CMC), clinical trial supplies manufacturing and distribution and Ph I-IV international clinical development. We focus on medical and clinical relevance from well-founded First-in-Man and Proof of Concept packages through delivery of cost and time effective dose-defining and pivotal trials, to post-registration support. These services are integrated through international regulatory affairs and project management and supported by state-of-the-art data systems. | |
Company: | Acambis plc |
Ticker Symbol & Exchange: | ACM, London Stock Exchange |
Media Contact: | Lyndsay Wright |
Phone: | 44 01223 275 300 |
E-mail: | ir@acambis.com |
Web: | www.acambis.com |
Acambis is a leading vaccine company developing novel vaccines, based in Cambridge, UK and Cambridge, Massachusetts, US. ChimeriVax platform vaccine candidates include: ChimeriVax-JE (partnered with sanofi pasteur and Bharat Biotech, excellent safety and efficacy profile shown in Phase 3), ChimeriVax-West Nile (in Phase 2), and ChimeriVax-Dengue, sanofi pasteur's tetravalent dengue vaccine (100% seroconversion to four dengue virus serotypes demonstrated in Phase 2). Acambis has the only vaccine in development against Clostridium difficile bacteria. Influenza programme targets a universal vaccine, for which a universal "˜A' strain vaccine is in Phase 1. The US FDA licensed ACAM2000 smallpox vaccine in August 2007. | |
Company: | Adhesives Research |
Media Contact: | Andrea Jackson |
Phone: | 717-227-3309 |
E-mail: | ajackson@arglobal.com |
Web: | www.adhesivesresearch.com |
Adhesives Research (AR) is a leading developer and manufacturer of custom adhesives, dissolvable films and laminates for the pharmaceutical and medical markets. We offer formulation, process development and analytical support for the development of components for transdermal and oral/mucosal delivery systems. Adhesives Research has developed custom-coated technology to create unique dissolvable films and custom adhesive systems for the delivery of functional ingredients found in pharmaceutical prescription and over-the-counter (OTC) products. We have the ability to manufacture clinical and commercial quantities in our cGMP compliant facilities located in Glen Rock, Pa and Limerick, Ireland. | |
Company: | Akruti Nirman Limited |
Ticker Symbol & Exchange: | AKRUTI & BSE |
Media Contact: | Mr. Ajay M. Pawar |
Phone: | 91-22-67037515 |
E-mail: | ajay@akrutiestate.com |
Web: | www.akrutiestate.com |
Akruti Nirman Limited is a leading player in the Real Estate Sector in India, involved in the creation of various sector specific infrastructure such as IT Parks, BT Parks, Commercial and Residential properties. It is presently involved in the development of India's largest BT Park in Gujarat with an aim to provide the impetus for a Biotech led Socio-Economic revolution in the State of Gujarat, by giving access to the most modern technologies & infrastructure, which ultimately fosters entrepreneurship, innovation and growth. The Park comprises Built to suit plots ( plug & play ), Loaded wet labs, Bioincubation centre, Animal House, pilot plant facility, microbiological labs, tissue culture labs, green house, logistic centre etc and also will house a residential/commercial township with modern amenities. | |
Company: | Almac Group Ltd |
Stand: | 42 |
Media Contact: | Stakeholder Communications |
Phone: | 44(0)28 3833 2200 |
E-mail: | info@almacgroup.com |
Web: | www.almacgroup.com |
Almac employs over 2,000 people throughout our extensive facilities in Europe and North America. Our integrated development services range from: Comprehensive genomic and bioinformatics services; Cancer genomics contract research; Route design & synthesis of APIs (including potent, peptide and chiral compounds); Synthesis and formulation of labelled compounds (pre-clinical and clinical) Formulation development; Manufacturing/blinding, packaging, randomized labelling and distribution of clinical supplies; Clinical trial technology solutions based on IVRS, Web and EDC; Commercial scale manufacture and distribution; Comprehensive analytical services; EU import testing and QP release for clinical and commercial product. | |
Company: | alphaGEN Co., Ltd. |
Media Contact: | Iwao Nozawa, Ph.D. |
Phone: | 81 3-3518-2838 |
E-mail: | i-nozawa@alphagen.jp |
Web: | http://www.alphagen.jp/e-index.html |
alphaGEN is a biopharmaceutical company which is focusing its R&D activities on siRNA drug for the treatment of ischemic diseases (such as PAD) and cancers. It has developed DNA/RNA chimeric double-stranded oligonucleotides (siChimera), which has enhanced stability, minimized off-target effects and immunostimulatory innate immune reactions without sacrifice of gene silencing efficiency. Its lead ALG-00412 is a siRNA targeting Int6 mRNA to induce HIF-2alpha-dependent angiogenesis for the treatment of a variety of ischemic diseases. It has been shown that ALG-00412 can be administered intramuscularly without carrier systems to generate arterioles and improve walking disability in intermittent claudication-like rat model. | |
Company: | Alston & Bird |
Media Contact: | Philippe Bennett |
Phone: | 001-212-210-9559 |
E-mail: | pbennett@alston.com |
Web: | www.alston.com |
Philippe's practice over the past twenty-five years has focused on litigation and licensing of intellectual property rights, trade secret and employee non-compete litigation, technology transfer transactions, and the negotiation of patent and trademark contracts and agreements. He has been trial counsel before various federal and state courts, and the International Trade Commission in a diverse range of cases involving pharmaceutical chemistry, classical chemistry, drug delivery systems, medical imaging and injector devices, cardiac pacemakers, and in biotechnology. Philippe has also developed in-house patent programs and contributed to the development of corporate IP strategies, and has been involved in numerous international mergers and acquisitions and directed extensive due diligence projects, and IP portfolio valuations. | |
Company: | Ambrilia Biopharma Inc. |
Ticker Symbol & Exchange: | TSX:AMB |
Media Contact: | Julie M. Thibodeau |
Phone: | (514) 751-2003 |
E-mail: | jthibodeau@ambrilia.com |
Web: | www.ambrilia.com |
Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company dedicated to the discovery and development of novel treatments for viral diseases and cancer. Ambrilia's product portfolio includes an HIV protease inhibitor program (with lead compound PPL-100), an HIV integrase inhibitor program, two new formulations of existing peptides (Octreotide and Goserelin), other tumor targeted peptides such as PCK3145 and the Tumor and tumor Vasculature Targeting (TVT) technology platform, as well as other anti-viral programs. Exclusive worldwide rights to PPL-100 and its related compounds have been granted to Merck & Co., Inc. in return for milestone payments and royalties. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. | |
Company: | Aquapharm Biodiscovery |
Stand: | SDI |
Media Contact: | Dr. Jason Cleaversmith |
Phone: | 44 1631 559391 |
E-mail: | jason.cleaversmith@aquapharm.co.uk |
Web: | www.aquapharm.co.uk |
Aquapharm Biodiscovery is the UK's premier marine biotechnology company, pioneering the discovery and development of novel bioactives & innovative production systems from marine microbes. The company has a substantial collection of unique marine bacteria and fungi (> 6,500) isolated from diverse and extreme environmental habitats. Through the use of proprietary technology, Aquapharm derives and develops new biologically active natural products from this collection, which have commercial applications in the nutraceutical, cosmeceutical and pharmaceutical sectors. Aquapharm focuses on the development of anti-infectives, anti-inflammatories, natural carotenoids and anti-oxidants through innovative fermentation based technology. | |
Company: | aRigen Pharmaceuticals, Inc. |
Media Contact: | Dr. Kyaw Min Oo |
Phone: | 81-3-5771-4532 |
E-mail: | kmo@arigen.jp |
Web: | www.arigen.jp |
aRigen Pharmaceuticals, Inc. is a leading Japanese drug discovery and development company working on NMEs for infectious diseases. With a vision of "Discovered in Japan for Global Health" we discover pharmaceutical compounds in Japan in co-operation with leading Japanese life scientists, and develop them into novel drugs for the global population. aRigen is the only biomedical venture in Japan advancing toward a specialty pharmaceutical company with a strong focus on infectious diseases. aRigen has currently 6 NMEs in clinical and clinical-ready stages. | |
Company: | Assign Group |
Stand: | 52 |
Media Contact: | Klaus Fischer, PhD |
Phone: | 43-1-403 3805-18 |
E-mail: | klaus.fischer@assigngroup.com |
Web: | http://www.assigngroup.com |
As a mid-sized European CRO we offer the full range of services in the development and conduct of clinical trials across the whole of Central, Eastern & Western Europe (clinical research, data management, biostatistics, medical writing and study drug management incl. QP release). Through our offices in Berlin, Vienna, Gliwice and Budapest, our multi-national professionals deliver highest quality in accordance with ICH-GCP, local, national and international legislation. Our customer-focus, reliability and responsiveness have led to stable and continuous growth over the past years. The Assign Group stands for tailor-made solutions in clinical research. | |
Company: | BAC BV |
Media Contact: | Kathryn Robertson |
Phone: | 01260 296 506 |
E-mail: | kj.robertson@northbankcommunications.com |
Web: | www.bac.nl |
Based in The Netherlands, BAC BV offers products and services for the affinity purification of biological materials from complex media. The Company's proprietary CaptureSelect® affinity ligands have been proven in a wide range of biological applications, including Life Science Research and Biomanufacturing. The CaptureSelect® technology, based on single chain antibody fragments, enables the design of ligands for almost any target, with high specificity, affinity and stability. The ligands are produced through an efficient animal-free Saccharomyces cerevisiae-based process. The unique properties of the products provide competitive benefits to their users in terms of reduced cost of purification, higher quality product, and increased flexibility in the purification process. | |
Company: | Bayer Schering Pharma AG |
Stand: | 59 |
Media Contact: | Oliver Renner |
Phone: | 49 172 328 3112 |
E-mail: | oliver.renner@bayerhealthcare.com |
Web: | www.bayerscheringpharma.de |
Bayer Schering Pharma AG is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, Hematology/Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. The company employs more than 40,000 people and markets its products in over 100 countries. Pro forma sales in 2006 totaled EUR 10 billion. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. | |
Company: | BIOALVO, SA |
Media Contact: | Luis Amado |
Phone: | 3.51218E+11 |
E-mail: | bioalvo@bioalvo.com |
Web: | www.bioalvo.com |
BIOALVO is the first Portuguese biotech company working on early stages of drug discovery. BIOALVO designs and develops innovative drug development programmes that generate potent and efficient drugs aimed at CNS and neurodegenerative disorders. Using its proprietary and flexible HTS systems, based on engineered living yeast cells with a human target, BIOALVO can accelerate and increase the efficiency of drug discovery in a cost competitive way (savings more than 60% of costs up to the pre-lead stage, when compared to lower values in specialized publications) generating potent drug candidates (narrowing of the hit list of potential drugs to 20% of those identified by common platforms) for its pipeline and for its partners. | |
Company: | Bio-Link Australia Pty. Ltd. |
Media Contact: | Paul Field, CEO, Bio-Link |
Phone: | 61.2.9209.4397 |
E-mail: | info@bio-link.com.au |
Web: | www.bio-link.com.au |
Bio-Link is a business development company based in Australia but working globally to support the commercialization of therapeutics and diagnostics. Clients are invited to select from a range of service modules including technology assessment; project management; identification and engagement of partners, benchmarking and full negotiation of deals. The Bio-Link portfolio of opportunities includes small molecule and peptide drug candidates, genetic and protein biomarkers and other technologies. Bio-Link has a valuable mix of technical and commercial skills developed at companies and institutions where members of the team have been previously employed in the USA, Europe and Australia, including Schering Plough, Novartis, Cytopia, Cellabs, Exlixis, Ascenion and other organizations. | |
Company: | BioMarck Pharmaceuticals, Ltd. |
Media Contact: | Scott Yates |
Phone: | 919-459-6452 |
E-mail: | scott@largemouthpr.com |
Web: | www.biomarck.com |
BioMarck Pharmaceuticals, Ltd. is a private biopharmaceutical company dedicated to the discovery and development of new drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation in patients with chronic obstructive pulmonary disease (COPD), asthma, chronic rhinitis and cystic fibrosis. The company is developing a first-in-class drug specifically targeting the over-secretion process. The new product is based on scientific concepts developed by Dr. Kenneth Adler, Professor of Cell Biology at North Carolina State University and a recipient of The American Thoracic Society's Scientific Achievement Award. For more information, please visit www.biomarck.com | |
Company: | BIOPHARM GmbH |
Media Contact: | Dr. B. Merz |
Phone: | 49 173 6683396 |
E-mail: | bmerz@biopharm.de |
Web: | www.biopharm.de |
BIOPHARM GmbH operates internationally, offering licenses and co-development opportunities to our partners for more than 20 years. Our proprietary human growth and differentiation factor rhGDF-5 shows very promising results in treating orthopaedic defects, rebuilding blood vessels and repair nerve lesions. Currently we develop an innovative cosmetic product against skin-aging. Furthermore we provide services to our customers: The analysis of classical and recombinant active substances and drugs and the implementation or development of various cell culture projects. We offer to our customers efficient job processing, professionalism, punctuality and the suitable infrastructure. | |
Company: | BioQuanta |
Media Contact: | Jean-Michel Mauclaire |
Phone: | 336 1316 7415 |
E-mail: | jmm@bioquanta.net |
Web: | www.bioquanta.net |
BioQuanta offers biopharmaceutical companies expert molecular modelling capabilities for design, validation and optimization of compounds and screened molecule libraries. Partnering with hospital laboratories, we offer a comprehensive approach combining in-silico and NMR with in-vitro and in-vivo experimental data generation. Our gold standard service relies on standardized quantum chemistry, molecular dynamics protocols and proprietary software tools that enable rationalization of highly reliable structure-activity prediction for proteins and receptors, target identification for a given effect, lead optimization and toxicity prediction. The fast delivery of reliable data on a drug and its interaction mechanisms with its target saves time and resources while reducing risks of failure during clinical development. Such data is required to regulatory approval for new drug application filing | |
Company: | BioSciences Research Institute, India. |
Phone: | 91 98410 84810 |
E-mail: | tonyindia@gmail.com |
Web: | www.bri.in |
BioSciences Research Institute (BRI) has been setup as a premier Institute for conducting Research and Advanced Training, in the field of BioSciences. The institute has been promoted as a Not-for-Profit organization for promoting the growth of BioSciences in India. The aim and vision of the institute is to provide a platform for individuals, professionals, R&D Organizations, Pharmaceutical & Software companies to utilize and harness the Indian biotechnology Potential. BRI is engaged in Bioinformatics Training, Research and Development, Offshore R&D Support and Bio utilities simulation and development. Our R&D Team specializes in improving and inventing techniques, methodologies and environments for research in Biotechnology. | |
Company: | CAS |
Phone: | 614-447-3600 |
E-mail: | help@cas.org |
Web: | www.cas.org |
CAS produces the world's largest databases for chemistry and related sciences. About 40% of CAS's content is biological. The CAS Registry, the world's largest substance database, contains records not only for organic and inorganic chemicals but also sequences from literature, patents, and Genbank. CAS produces Chemical AbstractsT, a family of databases available through the STN® network, the SciFinder® desktop research tool for scientists, SciFinder ScholarT for students, and STN AnaVistT for analysis and visualization, among other electronic search services. CAS records provide links to full-text articles and patents. In addition, CAS' ScienceIP® staff are available to provide expert searching. | |
Company: | Cellectricon |
Media Contact: | Susanne Fagerlund |
Phone: | 46 31 760 35 15 |
E-mail: | susanne.fagerlund@cellectricon.com |
Web: | www.cellectricon.com |
Cellectricon is a key innovator and solutions provider of advanced cell-based screening products to accelerate biotechnology and drug discovery. Cellectricon's cell-based screening solutions and product pipeline are aimed at critical bottlenecks in the drug discovery where today's products are inadequate. The company's launched products has received outstanding market acceptance including 9 of the 10 largest pharmaceutical companies. At Bio-Europe Cellectricon will present their cutting-edge screening systems that will transform drug discovery: -Cellaxess-HT - The world's first high throughput RNAi screening system -Dynaflow-HT - Next generation high throughput APC system for ion channel screening | |
Company: | Cellerix S.L. |
Media Contact: | Maria Pascual |
Phone: | 34918049264 |
E-mail: | mpascual@cellerix.com |
Web: | www.cellerix.com |
Cellerix is a clinical biopharmaceutical company that develops and produces innovative medicines based on the use of adult stem cells. It currently has two products undergoing clinical trials: Cx401 for the treatment of perianal fistulas (Phase III) and Cx501, for skin regeneration (Phase II). Cx401 and Cx501 are the two first cellular products to obtain orphan status by EMEA. The new generation of Cellerix products is based in the employment of allogeneic stem cells and is represented by Cx601 and Cx611, currently undergoing preclinical development for the treatment of fistulas and different alterations of the immune system. On August 6th, Cellerix announced the closing of a series B round, led by LSP, Ventech and YSIOS with co-investment by Novartis and Roche Venture Funds. On October 2nd, Cellerix also announced that it has outlicensed North American rights to Cx401 to Axcan Pharma. | |
Company: | ChemCon GmbH |
Media Contact: | reinhard.hirsch@chemcon.com |
Phone: | 49 (0) 761 5597 440 |
E-mail: | info@chemcon.com |
Web: | www.chemcon.com |
ChemCon is specialized in contract research and custom synthesis in the field of small molecular organic and inorganic chemistry. Our core competence is the development of synthetic routes and small scale manufacturing (mg to multi kg) of fine chemicals and Active Pharmaceutical Ingredients (APIs) from pre-clinical and all clinical phases to commercial material. We are equipped with excellent R&D- and production laboratories, FDA inspected clean-room facilities, and microbiological / chemical analytics. ChemCon is your expert partner for process transfer from R&D to cGMP compliant commercial production (with full GMP-documentation and Drug Master Files Type II). | |
Company: | CLEAN CELLS |
Stand: | Hall H, Booth 86 |
Media Contact: | Rolf CUYPERS |
Phone: | 33 2 51 09 27 57 |
E-mail: | rcuypers@clean-cells.fr |
Web: | www.clean-cells.fr |
Clean Cells is a French CRO offering a comprehensive biosafety testing program of in vitro and in vivo services supporting the process development of bioproducts (recombinant proteins, monoclonal antibodies, vaccines, cell and gene therapy products"¦) from initial R&D stages through clinical trials. Clean Cells has at its disposal over 4300 square feet of laboratory space in full compliance with American and European Pharmacopeia regulatory specifications at biosafety level II and III. This state of the art facility is designed to meet all requirements for biosafety controls (mycoplasma, sterility, viruses, residual DNA, endotoxins"¦) and cell characterization (isoenzymes, DNA finger printing, karyology...) Clean Cells differs from its larger competitors in its ability to offer very personalized services to its customers with a fast response time at a competitive cost. | |
Company: | Cobra Biomanufacturing Plc |
Ticker Symbol & Exchange: | CBF |
Media Contact: | Philip Ridley-Smith |
Phone: | 44 (0)1782 877298 |
E-mail: | philip.ridley-smith@cobrabio.com |
Web: | www.cobrabio.com |
Cobra Biomanufacturing is a company focused on a solution-led approach to biomanufacturing for the production of biopharmaceuticals, including recombinant proteins, protein conjugation, virus and plasmid DNA products up to Phase III. The company provides world-class process development solutions, cGMP contract manufacturing and a high level of analytical capabilities for the development of products from pre-clinical evaluation through to clinical trial manufacture. Cobra has an international base with major accounts in Europe, the U.S., Africa and Australasia. Our mission is to work in partnership with our customers to accelerate the clinical development of their products and to add significant value to their business. | |
Company: | CytRx Corporation |
Ticker Symbol & Exchange: | Nasdaq: CYTR |
Media Contact: | David Haen |
Phone: | (310) 826-5648 ext. 304 |
E-mail: | dhaen@cytrx.com |
Web: | www.CytRx.com |
CytRx Corporation is engaged in the development of human therapeutics based on its small molecule "molecular chaperone" amplification technology and RNAi therapeutics. The Company plans to start a Phase IIb trial in ALS with Arimoclomol, its lead small molecule candidate, by year end 2007. CytRx expects to start Phase II trials with Arimoclomol for stroke recovery and Iroxanadine for diabetic foot ulcers in the first half of 2008, subject to FDA clearance. CytRx intends to issue a dividend of shares of RXi Pharmaceuticals, its majority owned RNAi therapeutics subsidiary, and expects RXi will trade as a separate listed company. | |
Company: | DSM Biologics |
Media Contact: | Kevin Lesnewski |
Phone: | 973-257-8011 |
E-mail: | info.dsmpharaceuticals@dsm.com |
Web: | www.dsmpharmaceuticals.com |
DSM Biologics, a business unit of DSM Pharmaceutical Products, is a global provider of manufacturing technologies & services to the biopharmaceutical industry. Along with manufacturing services, DSM offers license and process development services utilizing PER.C6® human cell line as a production platform for recombinant proteins and monoclonal antibodies. The PER.C6® Technology Platform used in combination with DSM's XD process can achieve yields in excess of 10 g/l. This expertise provides biopharmaceutical companies pipelines with a turn-key biologic manufacturing solution, reducing cost, risk and drastically shorting time to first-in-man clinical trials. Contact DSM Biologics and see why more companies are licensing The PER.C6® human cell line than ever before. | |
Company: | Dynogen Pharmaceuticals, Inc. |
Media Contact: | Heather Savelle, Manager, Corporate Comm |
Phone: | 781.839.5149 |
E-mail: | hsavelle@dynogen.com |
Web: | www.dynogen.com |
Dynogen is a clinical stage company developing a portfolio of treatments for gastrointestinal and genitourinary disorders. The Company is focused on large and untapped markets in disease areas that severely impair a patient's quality of life, such as irritable bowel syndrome, gastroesophageal reflux disease and overactive bladder. The Company leverages its development expertise to identify promising clinical compounds and rapidly advance them towards registration. | |
Company: | Eden Biodesign |
Media Contact: | Sylvie Berrebi (De Facto Communications) |
Phone: | 44 20 7861 3838 |
E-mail: | s.berrebi@defacto.com |
Web: | http://www.edenbiodesign.com/ |
Eden Biodesign is a world leader in the provision of biopharmaceutical development and manufacturing expertise and now operates the new world class UK National Biomanufacturing Centre. The combination of the advanced facility and the expertise found in its people, mean Eden Biodesign has the scope and the capacity to handle over 95% of the products and processes found within the biopharmaceutical pipeline. -Recombinant protein therapies (antibodies and fragments) -Natural proteins -Gene therapies -Cell therapies -Vaccines (VLP, Cancer vaccines, whole cell vaccines) -Tissue engineering | |
Company: | Eurogentec SA - Biologics Division |
Media Contact: | Philippe Cronet, Business Unit Director |
Phone: | 32 4 366 6111 |
E-mail: | ph.cronet@eurogentec.com |
Web: | http://biologics.eurogentec.com |
Antibiotic free GMP plasmid DNA manufacturing. | |
Eurogentec has been selected by Delphi Genetics as the exclusive CMO for its antibiotic free StabyTM technology. Delphi's technology responds to the FDA's and EMEA's strong recommendations to move towards systems that are completely free from antibiotic resistance genes. The combination of Delphi's technology and Eurogentec's GMP biologics manufacturing experience will offer those developing plasmid DNA based drugs the latest in plasmid manufacturing technology. Eurogentec SA, based in Seraing, Belgium, offers services to the research, diagnostic and therapeutic markets. http://www.eurogentec.com. Delphi Genetics, based in Gosselies, Belgium, offers patented technology for DNA engineering and protein production. http://www.delphigenetics.com | |
Company: | European Patent Office |
Stand: | 77 |
Media Contact: | Mr. Rainer Osterwalder |
Phone: | 49 2399 1820 |
E-mail: | rosterwalder@epo.org |
Web: | www.epo.org |
The European Patent Office (EPO) is an international authority set up on the basis of the European Patent Convention to grant European patents using a unitary and centralized procedure. A single patent application in any of the three official languages - English, French or German - can provide patent protection in 32 states. The European patent system also offers a high level of legal certainty, as European patents are only granted following an in-depth examination and a comprehensive novelty search based on a collection of over 60 million documents. | |
Company: | FHR Consult |
Media Contact: | Dr. Fritz Rudert |
Phone: | 49-8106-995161 |
E-mail: | f.rudert@fhrconsult.com |
Web: | www.fhrconsult.com |
FHR Consult offers a diversified range of expert and hands-on consulting support in the areas of partnering, licensing, strategy, management, financing and competitive intelligence. We identify the most promising opportunities, help you with due diligence and commercial terms and actively support your negotiations to closing the deal. A particular focus is applied to all aspects of research, development and commercialization of biologics, like antibodies, and other targeted medicines. With our international network of partners and experts we give you the broad coverage, quality advice and tangible support for risk-balanced, fast decision making in complex corporate processes. | |
Company: | Foley & Lardner LLP |
Stand: | 76 |
Media Contact: | Richard C. Peet |
Phone: | 202.672.5483 |
E-mail: | rpeet@foley.com |
Web: | www.foley.com |
The Life Sciences Industry Team of Foley & Lardner LLP brings together experienced attorneys with knowledge of intellectual property (IP), venture capital, securities, tax, corporate and regulatory affairs, health care, antitrust, and international trade issues affecting all areas of biotechnology, pharmaceutical development, chemical, medical devices, and medicine. Our attorneys draw on the full resources of the firm's 19 offices across the United States, in Europe and Asia, assisting with all stages of a life-sciences business, from company formation and IP asset building to accessing capital and achieving commercial success. For more information, please visit our Web site at Foley.com. | |
Company: | Genzyme Pharmaceuticals |
Ticker Symbol & Exchange: | GENZ |
Media Contact: | Matthew Roe |
Phone: | 44 144 071 6204 |
E-mail: | matthew.roe@genzyme.com |
Web: | www.genzymepharmaceuticals.com |
Genzyme Pharmaceuticals, a division of Genzyme Corporation, provides an integrated resource of custom manufacturing, value-added technologies, and strategic relationships focused in the lipid, peptide, amino acid derivative, and drug delivery markets. Genzyme Pharmaceuticals and Pharmidex have formed a collaboration of science and skill to develop CerenseSM, a unique integrated solution to release the value of your CNS portfolio by unlocking the blood-brain barrier and measuring brain penetration. This is achieved through the combination of Genzyme Pharmaceuticals' patented CNS drug delivery technology and the unique expertise of Pharmidex to determine neuro-pharmacokinetics. Visit www.cerense.com to learn more. | |
Company: | Hana Biosciences |
Ticker Symbol & Exchange: | HNAB, NASDAQ |
Media Contact: | Remy Bernarda |
Phone: | 650-228-2769 |
E-mail: | remy.bernarda@hanabiosciences.com |
Web: | www.hanabiosciences.com |
Hana Biosciences is a development stage biopharmaceutical company engaged in the acquisition, development, and commercialization of products to strengthen the foundation of cancer care. The company has an oncology pipeline that includes four cancer therapeutics and one supportive care product candidate. The company's therapeutic products include three compounds that utilize their OPTISOME Nanoparticle Technology: Marqibo® (vincristine), Alocrest (vinorelbine) and Brakiva (topotecan). Marqibo is currently in a registration study in adult relapsed acute lymphoblastic leukemia, the rALLy study. Hana's supportive care product is Menadione for the treatment of skin rash associated with the use of epidermal growth factor receptor (EGFR) inhibitors. | |
Company: | HungaroTrial CRO |
Stand: | 4 |
Media Contact: | Dr. Lajos Sárosi |
Phone: | 36-1-203-21-34 |
E-mail: | info@hungarotrial.hu |
Web: | www.hungarotrial.hu |
HungaroTrial Contract Research Organization's declared goal is to join the human research programs of Pharmaceutical companies and Biotech companies by organizing and managing clinical operations in Central and Eastern Europe. We are conducting Phase I-IV clinical trials, medical device studies. Services: -Feasibility Analysis -Site Selection -Regulatory and EC Affairs -Hospital and Investigator Grant Consulting and Negotiation -Monitoring -Data management and Statistics -QA Site Audit To learn more about our activities, please visit our web site: www.hungarotrial.hu. Or send your questions or requests to info@hungarotrial.hu. | |
Company: | InterMed Discovery |
Media Contact: | Erik H. Metz |
Phone: | 49 231 9742 6072 |
E-mail: | erik.metz@intermed-discovery.com |
Web: | http://www.intermed-discovery.com/ |
InterMed Discovery, a MBO from BAYER HealthCare, is an independent company dedicated to the discovery and development based on Natural Products and endeavors to become the premiere company in discovering innovative lead compounds based on or derived from natural sources. We offer the broadest collection of genetic source material, a unique technology platform and comprehensive databases around chemical and biological data. InterMed Discovery provides products for therapeutic applications in the pharmaceutical industry, for the food industry and other life science areas. While focusing on developing our own discovery project portfolio for the food and pharmaceutical industry, we also offer excellent Natural Product research and discovery services. | |
Company: | Intertek ASG |
Media Contact: | Dr. Nick Crabb |
Phone: | 44 (0)161 721 1051 |
E-mail: | nick.crabb@intertek.com |
Web: | www.intertekasg.com |
Intertek ASG is a specialist CRO providing a broad range of advanced analytical and characterization services to pharmaceutical and biopharmaceutical clients. Services include method development, validation, and batch release analysis (e.g. for product and process related impurities) and regulatory characterization work (e.g. proof of structure, impurity characterization, detailed biopharmaceutical comparability studies, biopharmaceutical aggregation studies etc). Intertek ASG has experience across a diverse range of products including small molecule therapeutics, oligonucleotides, peptides, recombinant proteins, antibodies, vaccines and viral vectors. The laboratory has been inspected to GLP and GMP by the UK MHRA and to GMP by the US FDA. | |
Company: | IP Bewertungs AG (IPB) |
Stand: | CCH Hall/Booth no:32 |
Media Contact: | Juliane Ostler |
Phone: | 49 40 8787 90-00 |
E-mail: | info@ipb-ag.com |
Web: | www.ipb-ag.com |
IP Bewertungs AG (IPB) is one of Europe's leading consulting firms for intellectual property services such as patent evaluation, patent monetisation and patent management. On this year's Bio-Europe IPB presents various innovationsa, eg. a comprehensive system for the production of active ingredients such as for pharmaceutical products and technical enzymes, where the whole intact bacteria cell is utilized (whole cell catalyst) and a biotechnological basic technology for the production of pharmacological relevant active substances. aThe patents are the property of ZYRUS Beteiligungsgesellschaft mbH & Co. Patente I KG. | |
Company: | Italian Institute for Foreign Trade |
Stand: | 60 |
Media Contact: | Francesca Mondello |
Phone: | 39 06 5992 6606 |
E-mail: | f.mondello@ice.it |
Web: | http://www.italtrade.com/countries/europe/germany/ |
The Italian Institute for Foreign Trade - ICE, is the Government Agency that helps Italian SMEs to develop business and export opportunities worldwide. ICE organizes, in collaboration with Assobiotec, the Italian participation at BIO-Europe 2007, within the framework of the Special Project for Biotechnology and Nanotechnology, financed by the Ministry for International Trade. Please come and visit the Italian Pavilion (booth 60) and find out more about the Italian biotechnology sector! If you are interested in meeting our 15 Italian participants (http://www.italtrade.com/bioeurope.htm) don't hesitate to get in contact with all Italian companies by using the official partnering system. | |
Company: | Keryx Biopharmaceuticals |
Ticker Symbol & Exchange: | KERX |
Media Contact: | Lauren Fischer |
Phone: | 212-531-5965 |
E-mail: | lfischer@keryx.com |
Web: | www.kery.com |
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes, diabetes related diseases, cancer and nervous system disorders. Keryx pipeline includes: -Sulonex, for the treatment of diabetic nephropathy, presently in a pivotal Phase III and Phase IV program. -Perifosine, an oral anticancer agent that modulates AKT and other key signal transduction pathways in Phase 2. -Zerenex, an oral, iron-based phosphate binder in Phase II for hyperphosphatemia. -KRX-0701, for neuropathic conditions, phase II planned for 2008. -KRX-0501 is an orally available small molecule in phase I with the potential to treat neurological disorders via its ability to enhance nerve growth factor. | |
Company: | LAB Research |
Stand: | 19 |
Ticker Symbol & Exchange: | LRI |
Media Contact: | Cecilia Ponzi |
Phone: | (1) 450-973-2240 |
E-mail: | ponzic@labresearch.com |
Web: | www.labresearch.com |
LAB Research Inc., (LRI) is a leading in-vivo nonclinical contract research organization with facilities in Canada, Hungary and Denmark. We provide contract research services to the pharmaceutical, biotechnology, industrial chemical, agrochemical and medical device industries. LAB Research offers the full range of nonclinical studies necessary for the development of drugs intended for the treatment of human conditions or diseases or required for the certification or registration of products of non-medicament products. From discovery to IND/NDA, LAB Research provides unparalleled research excellence. | |
Company: | MacroGenics, Inc. |
Media Contact: | Sarah Kurz |
Phone: | 301-251-5172 |
E-mail: | kurzs@macrogenics.com |
Web: | www.macrogenics.com |
Founded in 2000, MacroGenics is a private, venture-backed biotechnology company that focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. With an experienced management team and a spectrum of fully integrated capabilities in monoclonal antibody product development, MacroGenics has developed technology platforms and a diverse product portfolio with several drugs currently in clinical testing, and others to enter clinical trials in the near future. | |
Company: | Marinomed Biotechnologie GmbH |
Media Contact: | Dr. Eva Prieschl-Grassauer |
Phone: | 0043/1/25077 4460 |
E-mail: | office@marinomed.com |
Web: | www.marinomed.com |
Marinomed is specialized in biotechnological research on marine organisms as source for new therapies. The company develops innovative drugs from natural resources for the treatment of diseases that have a high degree of unmet medical need. Marinomed cultivates marine organisms such as stony corals, soft corals, anemones, and sponges in aquaculture and in cell culture. This guarantees the reproducible source for any extraction and allows the induction of substance production in the animals or culture systems. Extracts from the organisms will be subjected to a screening program focussing on the therapeutic field of immunology and infectious diseases. | |
Company: | Mayer Brown LLP |
Stand: | 71 |
Media Contact: | Dr. Rüdiger Herrmann |
Phone: | 49 69 7941 1421 |
E-mail: | rherrmann@mayerbrown.com |
Web: | www.mayerbrown.com |
Mayer Brown is among the leading international business law firms, with more than 1,500 lawyers practicing in key business centers in North America, Europe and Asia. We providing comprehensive legal services to companies from the biotech, pharma, medical device and life science industries. Our representation ranges from some of the largest biotech and pharma corporations to start-up biotech, life science and bioinformatics companies. We also represent a significant number of financial investors, including banks, private equity and venture capital companies, as well as credit institutions and investment banks. Please visit our website for comprehensive contact information for all offices. | |
Company: | Millipore Corporation |
Ticker Symbol & Exchange: | MIL |
Media Contact: | Karen Marinella Hall |
Phone: | 978-715-1567 |
E-mail: | Karen_Hall@millipore.com |
Web: | www.millipore.com |
Millipore is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. Established in 1954 as a high performance filtration products and services company, Millipore has grown into a partner for Life Science customers through R&D investment, organic growth and acquisitions. Companies acquired include Chemicon, Upstate, Linco, and NovaSeptic AB, allowing Millipore to offer cell biology, life science research, drug target screening and upstream biomanufacturing tools and services. As a result, Millipore is able to provide solutions across the workflow continuum "” from research to development to production. Millipore is an S&P 500 company with more than 6,100 employees worldwide and operations in 47 countries. | |
Company: | Moberg Derma AB |
Media Contact: | Peter Wolpert and Tommy Nilsson |
Phone: | 46 522 307 00 |
E-mail: | info@mobergderma.se |
Web: | www.mobergderma.se |
Moberg Derma develops a portfolio of late-stage pharmaceuticals for skin diseases based on the Kaprolac® principle. The two lead products are in phase III clinical trials - K101 for Onychomycosis and K301 for Seborrheic Eczema. The first market approval is expected late 2009. The company will market and sell its products in the Nordic markets and in-license additional product rights to complement the portfolio. International commercialization will be through partners and discussions are ongoing with the aim to close a deal during first half of 2008. The company aims for an IPO at OMX Nordic Exchange in Stockholm in 2008/2009. | |
Company: | Movetis |
Media Contact: | Dirk Reyn |
Phone: | 32 475 96 52 57 |
E-mail: | dreyn@movetis.com |
Web: | www.movetis.com |
Movetis NV, based in Turnhout, Belgium, is a specialty pharmaceutical company focused on GI diseases. Movetis has a broad portfolio with four products in clinical development, including its lead product, Resolor® which is in Phase III, and four in preclinical, addressing important areas of unmet medical need, including Chronic Constipation, ascites, paediatric reflux, diabetic gastroparesis, severe dyspepsia and secretory diarrhoea. The current portfolio was licensed from Janssen Pharmaceutica NV, Belgium and Ortho-McNeil Pharmaceutical Inc. In 2006, Movetis secured a 49 million Euros series "˜A' financing from major European and US investors - one of the biggest series "˜A' rounds in Europe. | |
Company: | MPI Research |
Media Contact: | Lisa Lambertsen |
Phone: | 269.668.3336 |
E-mail: | lisa.lambertsen@mpiresearch.com |
Web: | www.mpiresearch.com |
MPI Research is a full service Contract Research Organization that serves the biotech and the pharmaceutical industries in meeting their preclinical and early clinical drug development research needs, from discovery to regulatory submission. Known for our state-of-the-art facilities, excellent study quality, regulatory experience, AAALAC accreditation, and GLP compliance, we partner with our Sponsors in delivering on time, high quality, innovative and cost-effective solutions. From single study protocols to multiple projects across our broad scope of services, we have the capacity and resources to start you studies promptly so that you can achieve your project milestones. For complete information, visit our website at www.mpiresearch.com. | |
Company: | Nereus Pharmaceuticals, Inc. |
Media Contact: | Pam Lord, Porter Novelli Life Sciences |
Phone: | 619-849-6003 |
E-mail: | plord@pnlifesciences.com |
Web: | www.nereuspharm.com |
Nereus Pharmaceuticals pursues novel sources of chemical diversity to discover and develop new therapeutics. Using its unmatched expertise in marine microbiology to identify unique biologically active compounds, the Company has placed two oncology drug candidates in Phase I clinical trials. NPI-2358, a tumor vascular disrupting agent, is being evaluated in patients with solid tumors and lymphomas, and the proteasome inhibitor NPI-0052 is being developed in patients with solid tumors, lymphomas and multiple myeloma. Nereus's discovery portfolio also includes potential drug candidates for cancer, infectious diseases and inflammation. For more information, visit www.nereuspharm.com. | |
Company: | Novozymes A/S |
Ticker Symbol & Exchange: | NZYMb; OMX Copenhagen |
Media Contact: | David Mead |
Phone: | 44 115 9553355 |
E-mail: | DVJM@novozymes.com |
Web: | www.novozymes.com |
Novozymes offers: -flexible licensing packages for protein expression, albufuse and cGMP manufacture of proteins. -Albufuse technology enables genetic fusion of a client's target protein to albumin at the molecular level: a cost effective, scalable system for the production of fully functional peptides and proteins. -for out-licensing a variety of antimicrobial peptides active against a number of serious bacterial and fungal infections. The lead compound Plectasin NZ2114 enters clinical phase I in 2008. -contract manufacturing services to the biopharmaceutical industry, Cell Bank preparation, GMP adaptation and scale-up of bioprocesses and GMP production for clinical trial and commercial products. | |
Company: | Oncolytics Biotech Inc. |
Ticker Symbol & Exchange: | ONC:TSX, NASDAQ:ONCY |
Media Contact: | Cathy Ward |
Phone: | 403.670.7370 |
E-mail: | cathyward@oncolytics.ca |
Web: | www.oncolyticsbiotech.com |
Oncolytics Biotech Inc. was formed in 1998 to develop its proprietary product, REOLYSIN®, as a potential therapeutic for a wide variety of human cancers. Oncolytics has completed six clinical trials with REOLYSIN® in Canada, the U.K. and the U.S. and is currently conducting seven Phase I or Phase II REOLYSIN® trials in the U.K. and the U.S. The current clinical program includes local or systemic delivery of REOLYSIN® as a monotherapy, and local or systemic delivery of REOLYSIN® in combination with radiation or chemotherapy for patients with advanced cancers. | |
Company: | Optimata Ltd. |
Media Contact: | Guy Malchi, CEO |
Phone: | 972-3-7519226 |
E-mail: | Guy@optimata.com |
Web: | www.optimata.com |
Optimata Ltd. is a modeling based biopharmaceutical company that develops computerized tools, Virtual Patient engines, for Navigating Drug Development towards better drugs at lower attrition rates. Optimata's predictive bio-simulation technology enables the identification of discontinued drug candidates and redirecting their path to market. Optimata Virtual Patient® (OVP) engine is a powerful, interactive, clinical trial optimization tool, enabling significant reductions in time-to-market and development costs from the pre-clinical phase through treatment personalization. Optimata's Technology Enables: -Drug repurposing -Enhanced drug competitive profile -Early "GO/NO-GO" development decisions -Drug safety profile -Optimal dosing schedules -Clinical indication selection/expansion | |
Company: | Oryzon Genomics |
Media Contact: | Group Inforpress |
Phone: | 0034 93 419 06 30 |
E-mail: | mmascarell@inforpress.es |
Web: | www.oryzon.com |
Oryzon Genomics is the first Spanish company in functional genomics and a paradigm of high growth in the emergent Spanish Biotech Sector. Based in Barcelona and launched in 2001 as a spin-off of the Spanish National Research Council (CSIC) and the University of Barcelona, Oryzon has an international staff of highly qualified scientists and is developing projects that are aimed at identify biomarkers focused on oncology and neurological disorders and, for certain uses, in Agrobiotechnology. The company is extending his activity from diagnostics to therapy through biologics, identifying and validating possible new therapeutic targets that could be used as a starting point for further development of new drugs based on a biological approach. | |
Company: | Oy Jurilab Ltd. |
Media Contact: | Tim Kirk |
Phone: | 358207219200 |
E-mail: | info@jurilab.com |
Web: | www.jurilab.com |
Jurilab is a Genetic Discovery company dedicated to applying its proprietary discoveries of genes and genetic markers associated with the root cause of common diseases and drug response across healthcare. The current focus of Jurilab's work is in the genetic background of metabolic diseases, often described under the umbrella of Metabolic Syndrome, including hypertension, type 2 diabetes, obesity and dyslipidemia. The product emphasis is on disease predisposition tests, which will support the advent of personalized medicine and nutrition, and on human-validated drug targets. | |
Company: | PAION AG |
Ticker Symbol & Exchange: | PA8, FSE |
Media Contact: | Dr. Peer Nils Schroeder |
Phone: | 49 241 4453-152 |
E-mail: | pn.schroeder@paion.de |
Web: | www.paion.de |
PAION, a biopharmaceutical company based in Aachen, Germany, aims to become a leader in developing and commercializing innovative drugs for the treatment of diseases for which there is a substantial unmet medical need, e.g. stroke and other thrombotic diseases. Since 11 February 2005, PAION is listed at the Frankfurt Stock Exchange (Prime Standard Official Market, Stock Symbol PA8, ISIN DE000A0B65S3). PAION's focus is currently on Desmoteplase, a plasminogen activator in PhIII development for ischaemic stroke. It was partnered with Forest Labs. and H. Lundbeck, but in 08/2007 Forest decided to return the license. PAION is now actively looking for a new partner for North America. | |
Company: | Pieris AG |
Media Contact: | Dr. Birgit Zech - Business Development |
Phone: | 49 8161 141 1400 |
E-mail: | info@pieris-ag.com |
Web: | www.pieris-ag.com |
Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins®, a novel class of targeted human proteins designed to diagnose and treat serious human disorders. Anticalins are engineered by Pieris from the scaffold of human lipocalins, a family of natural ligand binding proteins. Anticalins are selected to have prescribed binding properties with selectivity and affinity fundamentally similar to that of monoclonal antibodies. Being human in origin, Anticalins are predicted to have minimal immunogenicity in man. Where Anticalins benefit compared to conventional antibodies is in their small size (20 kDa), their robust physicochemical properties and their simple composition that together allow highly soluble, predictably stable products to be manufactured from bacteria. | |
Company: | Pharmahungary Group |
Stand: | 4 |
Media Contact: | Peter Ferdinandy, MD, PhD, MBA |
Phone: | 36 30 9250498 |
E-mail: | peter.ferdinandy@pharmahungary.com |
Web: | www.pharmahungary.com, www.cardiovasc.com |
Pharmahungary is an emerging preclinical and clinical CRO providing innovative and cost-effective preclinical and clinical R&D solutions for pharma/biotech companies, focusing on cardiovascular (cardiovasc) and metabolic diseases (diabetes, hyperlipidemia, atherosclerosis, obesity etc). Our custom designed innovative R&D systems (innoRD) significantly reduce the duration of drug development. Quality is ensured by highly trained management with top scientific excellence. Pharmahungary runs some in-house R&D projects currently focusing on the development of inhibitors of peroxynitrite and its downstream cellular target matrix metalloproteinases (www.mmpharma.com), as well as activators of biglycan for cardiovascular indications. Pharmahungary is seeking for partners to develop joint venture projects. | |
Company: | Pharmalicensing Ltd. |
Media Contact: | Pete Tan |
Phone: | 44 (0)1904 520 460 |
E-mail: | pete.tan@pharmalicensing.com |
Web: | www.pharmalicensing.com |
Pharmalicensing is the leading online global resource for partnering, licensing and business development within the life science and biopharmaceutical industry. Our unique partnering services complement and enhance business development activity throughout the deal making process, from finding partners to making the deal. Attracting an audience of over 60,000 visitors per month, Pharmalicensing provides a central meeting point for potential partners, offering company profiles to promote licensing opportunities, flexible consultancy services, business intelligence, and up to date industry news. Pharmalicensing also offers advertising and sponsorship opportunities on its website and in its newsletters. Visit www.pharmalicensing.com | |
Company: | Pharmarama |
Stand: | 35 |
Media Contact: | Paul Sagan, Sharon Merrill Associates |
Phone: | 1 617 542 5300 |
E-mail: | psagan@investorrelations.com |
Web: | www.pharmarama.com |
Pharmarama is a licensed wholesaler and importer of licensed and unlicensed medicines, based in London, England, with offices located in the United States and Germany. The company was founded in 2006 by Ben Rabin, Chairman of BR Pharma, to work in collaboration with BR Pharma as a single point of contact for the sourcing, repacking, blinding and distribution of comparator drugs worldwide. BR Pharma has more than a decade of experience working with the world's leading pharmaceutical companies and clinical research organizations sourcing and procuring pharmaceutical products for clinical trials as well as in providing services for named patient programs. | |
Company: | PHOTO DYNAMIC THERAPY LLC / PDT® |
Media Contact: | Günther HOFMANN |
Phone: | 43 664 33 7777 5 |
E-mail: | gh@pdt.at |
Web: | www.pdt.at |
PHOTONIC TUMOR THERAPY is intelligent controlled laser light adapted to patients' individual needs. FOTESI® docks on tumor cells and the laser light matching the properties of both causing the least cytotoxic tumor cell switch-off but protecting healthy cells. Treatment in the curative and palliative setting at bile duct, bladder, cardia, cervix, colon, esophagus, lung, pancreas and rectum. PDT® provides a clinical service on cost per treatment with procedural advice, SOPs, hands-on support and the PDT® SYSTEM to ensure treatment quality. The strong demand of PDT®'s non-invasive tumor treatment requires the capacity upscale by strategic partnerships for worldwide roll out. | |
Company: | Poniard Pharmaceuticals |
Ticker Symbol & Exchange: | Nasdaq:PARD |
Media Contact: | Brendan Doherty |
Phone: | 650-745-4425 |
E-mail: | bdoherty@poniard.com |
Web: | www.poniard.com |
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancer, as well as a Phase 1 clinical trial of oral picoplatin in solid tumors. For more information, visit www.poniard.com. | |
Company: | Premier Research Group |
Ticker Symbol & Exchange: | PRG (AIM London) |
Media Contact: | Jessica Barag |
Phone: | 1 (215) 282-5391 |
E-mail: | jessica.barag@premier-research.com |
Web: | www.premier-research.com |
Premier Research is a leading solutions-driven CRO leveraging our commitment to therapeutic focus and scientific expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. We operate in more than 30 countries across Europe and North America. We offer a comprehensive selection of services, including clinical trial management, medical and safety management, data management, biostatistics, medical writing, IVRS, regulatory affairs, quality assurance, and dedicated clinical sites. We are a leader in clinical research for Analgesia, Neuroscience, Oncology, and Infectious Disease and have a breadth of experience in medical device and pediatric clinical research. | |
Company: | Pyxis Discovery B.V. |
Media Contact: | Alexandrine Cheronet |
Phone: | 31 15 2600972 |
E-mail: | ac@pyxis-discovery.com |
Web: | www.pyxis-discovery.com |
Pyxis Discovery is a knowledge based company focusing on novel small molecules to accelerate drug discovery programs. Pyxis Discovery develops proprietary tools to explore the bioactive chemical space, design and identify novel small molecules and to select optimal properties for early stage drug candidates. Pyxis Discovery offers lead discovery services: proprietary screening platform for Proteases (MMPs, Serines, Cysteines and Aspartyls). Smart Libraries: small molecule screening sets specifically designed to address the current need of the drug discovery industry (high quality, stringent pysico-chemical properties, medicinal chemistry fast follow-up...) Fragment Libraries: fragment molecule screening sets designed for NMR screening. | |
Company: | QUALITY ASSISTANCE |
Media Contact: | Ms. Caroline Cajot |
Phone: | 32 71 53 47 81 |
E-mail: | infos@quality-assistance.com |
Web: | www.quality-assistance.com |
Quality Assistance is a leading European Contract Research Organisation assisting the (bio)pharmaceutical industries with the development of their products. We can provide a full service package compliant with the highest quality standards required by the FDA and EMEA. Our objective is to help our customers bring their products to the market efficiently. Our assets: "¢25 years experience "¢90 highly-qualified employees "¢3 200 m² of laboratories (5 000 m² by end 2007), including environmental chambers, and cell culture and BL2 & BL3 facilities "¢Accredited ISO 17025, recognized GMP, certified GLP and inspected by the FDA (no 483s issued) | |
Company: | Richter-Helm BioTec |
Stand: | No. 5 |
Media Contact: | Dr. Astrid Brammer |
Phone: | 49-40-55905-801 |
E-mail: | info@richter-helm-biotec.eu |
Web: | www.richter-helm-biotec.eu |
Richter-Helm BioTec, formerly known as Strathmann Biotec, is a dynamic and expanding biotechnology company based in Hamburg, Germany. Richter-Helm offers highly specialized contract development and manufacturing services for microbial production of biopharmaceuticals, namely recombinant proteins and plasmid DNA and vaccines. Additionally to our contract development and manufacturing business, Richter-Helm is seeking for interesting biopharmaceutical development projects for its own pipeline and for co-development with partners. Based on long standing experience in the area of protein expression systems, plasmid-DNA technologies, fermentation as well as downstream processing Richter-Helm is in the position to offer first class services to our clients and partners. | |
Company: | Rottapharm S.p.A. |
Media Contact: | Dr. Marliese Annefeld |
Phone: | 0039 039 7390 308 |
E-mail: | marliese.annefeld@rottapharm.com |
Web: | www.rottapharm.com |
Rottapharm is an Italian multinational pharmaceutical group, headquartered in Monza, with branches in over 80 countries worldwide. Since its inception, Rottapharm has been primarily focusing on research. The group's traditional research fields in the gastrointestinal/digestive area and in the osteo-articular/rheumatology area have been extended, through intensive activity, to include the fields of hormone replacement therapy/women's health/gynaecology and, more recently, the cardiovascular, respiratory tract and central nervous system areas. In August 2007, Rottapharm acquired the pharmaceutical company Madaus Pharma; this acquisition represents an important turning point for Rottapharm, in terms of R&D synergies and marketing growth. | |
Company: | SciClone Pharmaceuticals, Inc. |
Ticker Symbol & Exchange: | NASDAQ:SCLN |
Media Contact: | Angela Bitting |
Phone: | US: 925-462-1106 |
E-mail: | a.bitting@comcast.net |
Web: | www.sciclone.com |
SciClone Pharmaceuticals is a biopharmaceutical company engaged in developing therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN® (thymalfasin) is in late-stage trials for malignant melanoma and hepatitis C virus (HCV). ZADAXIN is approved for sale in select markets internationally, principally in China where SciClone has an established sales and marketing operation. A key part of SciClone's strategy is to leverage its advantage and broaden its portfolio in China by in-licensing or acquiring the rights to other products, such as DC BeadTM. For the U.S., SciClone's clinical-stage drug development candidates are RP101 for pancreatic cancer and SCV-07 for HCV. | |
Company: | Select Greater Philadelphia |
Media Contact: | Nicole Blatcher |
Phone: | 215.240.0076 |
E-mail: | nblatcher@selectgreaterphila.com |
Web: | http://www.selectgreaterphila.com |
Select Greater Philadelphia (Select) is an economic development organization dedicated to marketing the Greater Philadelphia region as a premier business location. Select serves as a support system and information resource for companies in the United States and abroad as they consider a new location on the Northeastern Seaboard. Select is a private, non-profit organization that focuses its resources on enhancing the profile and image of the region's business community. The Greater Philadelphia region encompasses 11 counties in northern Delaware, southern New Jersey and southeastern Pennsylvania, in close proximity to New York City and Washington, D.C. For more information, visit www.selectgreaterphiladelphia.com. | |
Company: | Selvita |
Media Contact: | Pawel Przewiezlikowski |
Phone: | 48 602 277 771 |
E-mail: | Pawel.Przewiezlikowski@selvita.com |
Web: | www.selvita.com |
Selvita is an innovative biotech company from Poland. We serve our clients from the biotech and pharmaceutical industry with a comprehensive set of solutions targeted at lowering the cost and accelerating the introduction of new drugs to the market. We employ a highly specialized team of professionals with medical, chemistry, pharmacy, molecular biology, biotechnology and IT background and enjoy a very good cooperation with leading research institutes and universities from Poland, Europe and USA. We conduct our own innovative research projects for the pharmaceutical customers in collaboration with leading universities and institutes and implement advanced data processing solutions for the customers from biotechnology and pharmaceutical industry, including bioinformatics applications in the area of genomics, proteomics, pharmacogenomics, PK/PD modeling and cheminformatics. | |
Company: | SGX Pharmaceuticals, Inc. |
Ticker Symbol & Exchange: | NASDAQ:SGXP |
Media Contact: | Jason Spark |
Phone: | 619.849.6005 |
E-mail: | media@sgxpharma.com |
Web: | www.sgxpharma.com |
SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The SGX oncology pipeline includes drug candidates from its FAST (TM) drug discovery platform, such as next generation BCR-ABL inhibitors being developed by SGX and in partnership with Novartis, MET tyrosine kinase inhibitors, including SGX523, and potent JAK2 inhibitors. SGX's lead product candidate, SGX523, is a novel, orally bioavailable small-molecule inhibitor of the cMET receptor tyrosine kinase, which is implicated in a broad range of solid tumors, including lung, colon, prostate, gastric, and kidney cancers. SGX is targeting IND filing for SGX523 in the first quarter of 2008. | |
Company: | SIRO Clinpharm |
SIRO Clinpharm is a leading full service Indian CRO, more than a decade old, with expertise in Clinical Trial Management; CDM & Biometrics; Medical Writing, CTS & QA and working with most of the top ten global biotech & pharmaceutical companies. It has established its footprint in the US as well and has set up office in Princeton, New Jersey. Senior leadership, a focus on regulatory compliance and training, flexibility in business models and the credo of delivering at any cost are key differentiators. The winner of Proximare Inc's "Best Indian CRO" in 2005 as well as the Frost & Sullivan's "Partner of Choice Award" for phase II and III trials in 2007, SIRO has been at the forefront in the clinical research industry in India. | |
Company: | SynCo Bio Partners B.V. |
Media Contact: | Joanne McCudden |
Phone: | 31 655 34 80 74 |
E-mail: | joanne_mccudden@synco-biopartners.com |
Web: | www.syncobio.com |
SynCo Bio Partners is a GMP-licensed bulk product CMO with in-depth clinical and commercial production experience with mammalian and microbial systems. This has been acquired by making over 250 batches of our clients' vaccine and protein-based products in the last seven years. Financially stable and focused solely on biopharmaceuticals, SynCo Bio Partners acts as a strategic, long-term partner delivering your product on time and to the highest quality standards. All our staff are committed to exceeding customer expectations and believe that taking a truly collaborative approach to manufacture is the key to a successful outcome. | |
Company: | Talentmark |
Media Contact: | Richard M. Adams |
Phone: | 44 207 229 2266 |
E-mail: | richard.adams@talentmark.com |
Web: | www.talentmark.com |
For over 35 years, Talentmark has focused on executive recruitment within the healthcare industry. In that time we have become a trusted and unrivalled source of expertise to a prestigious portfolio of international clients across all industry sectors - from mainstream pharmaceuticals to niche technologies. Today start-up organizations and major multinationals alike continue to select Talentmark as their preferred partner in healthcare recruitment. Clients choose us for many reasons. Our friendly, client-centred approach. Our intimate knowledge of the market. Our extensive networks, our insight into market trends, our ability to provide benchmarking intelligence on reward Packages. Whatever we deliver consistently. | |
Company: | Teva Pharmaceutical Industries Ltd. |
Phone: | 972-3-914-8157 |
E-mail: | Liana.patt@teva.co.il |
Web: | www.tevapharma.co.il |
Teva Pharmaceutical Industries is among the world's top 20 pharmaceutical companies, specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals. In our Innovative business, we are actively seeking in-licensing of early- and mid-stage therapeutics based on promising preclinical pharmacological proof of concept (at a minimum) for potential therapies that answer a significant unmet need in "niche" markets with a focus on therapies for CNS, autoimmune diseases and oncology. Teva currently markets Copaxone® for treatment of MS, with global 2006 sales of over $1.4B, and Azilect® for treatment of PD. Teva's advanced innovative pipeline includes treatments for MS, PD, AD, and Cancer. | |
Company: | TRANSAT |
Media Contact: | Sophie CHAPPUIS |
Phone: | 33 472 791 360 |
E-mail: | transat@transatbiotechnology.com |
Web: | www.transatbiotechnology.com |
TRANSAT, a research partner from gene to therapy, propose customized services: -Cellular engineering: customized cellular models by RNAi & gene over expression, cellular transfection, vectorology, immortalization, siRNA design & validation -RNAi libraries: Ready to use and functionally validated -Interfence screening, classic or differential, functional & robust assays development. TRANSAT's customized services are fully adapted to elucidating pathological mechanisms: identification of physio-pathological gene activity, target validation; Identification, characterization and optimization of drug candidate molecules, screening of selected molecules and evaluation of toxicity. ...and developing tomorrow's therapies: oncology, obesity, diabetes, cardiovascular diseases, virology, diseases of the central nervous system, dermatology | |
Company: | Wacker Biotech GmbH |
Stand: | 10 |
Media Contact: | Rachela Mohr |
Phone: | 49 89 6279-1636 |
E-mail: | rachela.mohr@wacker.com |
Web: | www.wacker.com/biologics |
Wacker Biotech is a contract manufacturer of biopharmaceuticals with more than 20 years of experience of microbial systems. We provide full service from developing efficient and easily scalable processes to GMP-manufacturing for clinical trials and commercial supply combined with high-quality analytical services. Our multi-product facilities have been regularly audited by authorities and clients. We have a strong track record and experience from Phase I to Phase III. Our proprietary technologies are: an E. coli based secretion system for high-yield production of correctly folded proteins in the culture broth; and a high-cell-density fermentation technology resulting in exceptionally high biomass yields and optimal volumetric productivity. | |
Company: | WoodMackenzie |
Phone: | 44(0) 131 243 4255 |
E-mail: | pharma@woodmac.com |
Web: | www.woodmacresearch.com |
Wood Mackenzie has been providing its unique range of research products and consulting services to the Life Sciences industry for over 30 years. With its foundation in quality analysis, detailed industry understanding and wealth of experience, Wood Mackenzie is able to offer clients a unique skill combination that sets the company apart from other solution providers. Wood Mackenzie's market proposition is based on its ability to provide forward-looking commercial insight that enables clients to make better business decisions. The company employs over 500 staff making it one of the largest Energy and Life Sciences research and consulting companies in the world. Wood Mackenzie has global presence including offices located in Edinburgh, London, Boston and New York. For more information visit: www.woodmac.com/pharmabiotech | |
Company: | XENOBLIS |
Media Contact: | Françoise Brée |
Phone: | 33(0)2 99 23 46 46 |
E-mail: | francoise.bree@xenoblis.com |
CRO operating in the DMPK domain, Xenoblis has a strong expertise in in-vitro experiments (GLP inspected since 1994). Our services include all types of drug-drug interaction studies, clearance prediction, metabolic stability, metabolic profiling, interspecies comparisons, intestinal/BBB/skin passage, binding to plasma proteins. With a direct access to assay systems (human and animal hepatocytes, plasma/skin/brain endothelial cells, microsomes, etc.), our turnover times are short. Contact us for a quotation. | |
Company: | XOMA Ltd. |
Ticker Symbol & Exchange: | XOMA |
Media Contact: | Greg Mann |
Phone: | 510-204-7270 |
E-mail: | mann@xoma.com |
Web: | www.xoma.com |
XOMA is a leader in the discovery, development and manufacturing of therapeutic monoclonal antibodies (mAbs). XOMA's mAb platform includes leading commercial antibody display phage libraries, hybridoma, Human Engineering, affinity maturation technologies, and a fully integrated product development infrastructure, including cell line and process development, preclinical and clinical functions, and manufacturing. XOMA's pipeline includes both proprietary products and collaborative programs. XOMA receives royalties for RAPTIVA® and LUCENTIS®. Other strategic collaborations include Novartis International AG (formerly Chiron Corporation), Schering-Plough Corporation, Takeda Pharmaceutical Company Ltd. and Lexicon Genetics. XOMA has Human Engineering agreements with AVEO Pharmaceuticals, Inc. and Attenuon, LLC. |
Note to Editors: Business Wire's PressPass allows you to create free, custom Web, RSS, and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content, experts, company profiles, email alerts, survey services and other media services.
Note to Event Organizers: Add your trade show, conference, or event to http://www.tradeshownews.com, Business Wire's online event calendar. For information, email tradeshow (at) businesswire.com.